AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34351414 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 2q16 group
Number of subjects: 402
Study 34351414 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 2q8/PRN group
Number of subjects: 402
Study 34727737 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 161
Study 34727737 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 161
Study 32150297 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib maintenance (1·3 mg/m2 intravenously once every 2 weeks, for 2 years)
Number of subjects: 60
Study 32150297 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 60
Study 34402959 — intervention group
Group type: EXPERIMENTAL
Intervention: SADI-GP (pylorus-preserving single-anastomosis duodeno-ileal bypass with gastric plication)
Number of subjects: 17
Study 34402959 — intervention group
Group type: EXPERIMENTAL
Intervention: SADI-GP
Number of subjects: 17
Study 32434454 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb robotic training
Number of subjects: 50
Study 32434454 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy
Number of subjects: 50
Study 35729612 — intervention group
Group type: EXPERIMENTAL
Intervention: Community delivery of IPTp by community health workers
Number of subjects: 1057
Study 35729612 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving IPTp at health facilities
Number of subjects: 1057
Study 32140428 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevalence assessment
Number of subjects: 634
Study 32140428 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of diabetes
Number of subjects: 634
Study 32140428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension prevalence among diabetics
Number of subjects: 634
Study 32140428 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with diabetes
Number of subjects: 634
Study 34626001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led comprehensive geriatric assessment (CGA)-based intervention
Number of subjects: 33
Study 33755863 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab plus EOX (ZOL/EOX)
Number of subjects: 143
Study 33755863 — intervention group
Group type: COMPARATOR
Intervention: EOX alone
Number of subjects: 143
Study 33107002 — intervention group
Group type: EXPERIMENTAL
Intervention: High coaching group
Number of subjects: 40
Study 33107002 — intervention group
Group type: COMPARATOR
Intervention: Low coaching group
Number of subjects: 40
Study 35006086 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital delivery of audit and feedback intervention
Number of subjects: 2552
Study 35006086 — intervention group
Group type: COMPARATOR
Intervention: Postal delivery of audit and feedback intervention
Number of subjects: 2552
Study 35006086 — intervention group
Group type: COMPARATOR
Intervention: Comparison of digital vs postal delivery
Number of subjects: 2552
Study 33472650 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-directed intervention (monetary incentive for mRDT performance)
Number of subjects: 89
Study 33472650 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-directed intervention (free ACT for positive mRDT)
Number of subjects: 89
Study 33472650 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined provider- and client-directed interventions
Number of subjects: 89
Study 33472650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study 32280042 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week, 4-site intradermal (ID) rabies vaccination without ERIG (Group 1)
Number of subjects: 397
Study 32280042 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week, 4-site intradermal (ID) rabies vaccination with ERIG (Group 2)
Number of subjects: 397
Study 32280042 — intervention group
Group type: COMPARATOR
Intervention: 28-day, 2-site (2-2-2-0-2) ID regimen with ERIG (Group 3)
Number of subjects: 397
Study 32280042 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated PEP vaccination at Year 5
Number of subjects: 397
Study 32280042 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week, 4-site ID regimen with PVRV
Number of subjects: 397
Study 36208719 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMS 2.0 (mobile phone-delivered intervention including phone coaching and text message support)
Number of subjects: 338
Study 36208719 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (control)
Number of subjects: 338
Study 35441849 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower oxygenation target (8 kPa)
Number of subjects: 2928
Study 35441849 — intervention group
Group type: COMPARATOR
Intervention: Higher oxygenation target (12 kPa)
Number of subjects: 2928
Study 612365097 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-9054 (0.003%, 30 mug/mL) once daily for 28 days
Number of subjects: 123
Study 612365097 — intervention group
Group type: COMPARATOR
Intervention: Xalatan (0.005%, 50 mug/mL) once daily for 28 days
Number of subjects: 123
Study 612365097 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-9054
Number of subjects: 123
Study 35373861 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterbirth
Number of subjects: 1260
Study 35373861 — intervention group
Group type: COMPARATOR
Intervention: Nonwaterbirth
Number of subjects: 1260
Study 33711380 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg intravitreal pegcetacoplan
Number of subjects: 246
Study 33711380 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 246
Study 32757523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 1882
Study 32757523 — intervention group
Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 1882
Study 34525247 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive 800mg of intravenous ibuprofen plus 1000mg of intravenous paracetamol (Group IP)
Number of subjects: 69
Study 34525247 — intervention group
Group type: COMPARATOR
Intervention: Only 1000mg of intravenous paracetamol (Group P)
Number of subjects: 69
Study 33242754 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg, days 1–4)
Number of subjects: 218
Study 33242754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 35272114 — intervention group
Group type: EXPERIMENTAL
Intervention: GLIM criteria
Number of subjects: 468
Study 35272114 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-SGA
Number of subjects: 468
Study 34386279 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation-based NM training
Number of subjects: 34
Study 34386279 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 32558305 — intervention group
Group type: EXPERIMENTAL
Intervention: topical nepafenac (1 mg/ml) 1 drop 3 times per day for 3 days before surgery
Number of subjects: 73
Study 32558305 — intervention group
Group type: COMPARATOR
Intervention: not receiving topical nepafenac (control group)
Number of subjects: 73
Study 35697571 — intervention group
Group type: EXPERIMENTAL
Intervention: Single booster dose of 4CMenB in the infant + preschool group
Number of subjects: 2
Study 35697571 — intervention group
Group type: EXPERIMENTAL
Intervention: Single booster dose of 4CMenB in the infant group
Number of subjects: 2
Study 35697571 — intervention group
Group type: COMPARATOR
Intervention: Two doses of 4CMenB in naïve age-matched controls (adolescent 2 group)
Number of subjects: 2
Study 32445881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (Arbidol and IFN-α2b)
Number of subjects: 141
Study 32445881 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy group (IFN-α2b inhalation for 10–14 days)
Number of subjects: 141
Study 36442480 — intervention group
Group type: EXPERIMENTAL
Intervention: Frankincense-based herbal product (FHP)
Number of subjects: 120
Study 36442480 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 120
Study 36442480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33640917 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 457
Study 33640917 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 457
Study 33355268 — intervention group
Group type: EXPERIMENTAL
Intervention: Indashyikirwa programme (21-session curriculum)
Number of subjects: 1654
Study 33355268 — intervention group
Group type: COMPARATOR
Intervention: VSLA as usual (control)
Number of subjects: 1654
Study 33541815 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Olive Leaf Extract (OLE) cream
Number of subjects: 66
Study 33541815 — intervention group
Group type: COMPARATOR
Intervention: 5% Acyclovir cream
Number of subjects: 66
Study 32851775 — intervention group
Group type: EXPERIMENTAL
Intervention: FOVEA program (8 weeks, 2 hours/week)
Number of subjects: 139
Study 32851775 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group
Number of subjects: 139
Study 35816621 — intervention group
Group type: EXPERIMENTAL
Intervention: Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)
Number of subjects: 121
Study 35816621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 33411233 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-Parent Psychotherapy (CPP)
Number of subjects: 198
Study 33411233 — intervention group
Group type: COMPARATOR
Intervention: Control group (DC)
Number of subjects: 198
Study 33411233 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed comparison group (NC)
Number of subjects: 198
Study 34328264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic brushing (SB)
Number of subjects: 32
Study 34328264 — intervention group
Group type: COMPARATOR
Intervention: Manual brushing (MB)
Number of subjects: 32
Study 32683737 — intervention group
Group type: EXPERIMENTAL
Intervention: WeClick mobile phone application (4-week access)
Number of subjects: 193
Study 32683737 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (4-week wait)
Number of subjects: 193
Study 36004391 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Diet (LCD)
Number of subjects: 39
Study 36004391 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Carbohydrate Diet (SCD)
Number of subjects: 39
Study 36004391 — intervention group
Group type: COMPARATOR
Intervention: General diabetes education (Control)
Number of subjects: 39
Study 34106237 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Care Smoking Cessation Intervention
Number of subjects: 0
Study 34106237 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis including unit as a covariate
Number of subjects: 0
Study 34106237 — intervention group
Group type: EXPERIMENTAL
Intervention: Missing equated to smoking
Number of subjects: 0
Study 32987892 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanin intake
Number of subjects: 249
Study 32987892 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 249
Study 32987892 — intervention group
Group type: COMPARATOR
Intervention: Low anthocyanin intake and low physical activity
Number of subjects: 249
Study 35315226 — intervention group
Group type: EXPERIMENTAL
Intervention: Description condition (problem framing: gain/loss)
Number of subjects: 320
Study 35315226 — intervention group
Group type: COMPARATOR
Intervention: Experience condition (problem framing: gain/loss)
Number of subjects: 320
Study 35315226 — intervention group
Group type: EXPERIMENTAL
Intervention: General problem framing
Number of subjects: 320
Study 35315226 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific problem framing
Number of subjects: 320
Study 32681665 — intervention group
Group type: EXPERIMENTAL
Intervention: VL50
Number of subjects: 64
Study 32681665 — intervention group
Group type: EXPERIMENTAL
Intervention: VL15
Number of subjects: 64
Study 32681665 — intervention group
Group type: EXPERIMENTAL
Intervention: VL0
Number of subjects: 64
Study 32681665 — intervention group
Group type: EXPERIMENTAL
Intervention: VL25 and VL50
Number of subjects: 64
Study 34936990 — intervention group
Group type: EXPERIMENTAL
Intervention: Group visit intervention (GV)
Number of subjects: 116
Study 34936990 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study 32908283 — intervention group
Group type: EXPERIMENTAL
Intervention: AI intervention
Number of subjects: 0
Study 32908283 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 35681220 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) initiated < 48 hours from ICU admission
Number of subjects: 626
Study 35681220 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 626
Study 35681220 — intervention group
Group type: COMPARATOR
Intervention: Delayed enteral nutrition (DEN) initiated > 48 hours from ICU admission
Number of subjects: 626
Study 35681220 — intervention group
Group type: COMPARATOR
Intervention: Delayed enteral nutrition (DEN)
Number of subjects: 626
Study 34967353 — intervention group
Group type: EXPERIMENTAL
Intervention: nano-modified Runji ointment
Number of subjects: 80
Study 34967353 — intervention group
Group type: COMPARATOR
Intervention: placebo ointment
Number of subjects: 80
Study 33916877 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) hypercaloric diet
Number of subjects: 17
Study 33916877 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Protein (NP) hypercaloric diet
Number of subjects: 17
Study 33916877 — intervention group
Group type: COMPARATOR
Intervention: Control Diet (CD)
Number of subjects: 17
Study 33320267 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-to-peer (P2P) support
Number of subjects: 448
Study 33320267 — intervention group
Group type: COMPARATOR
Intervention: Standard community services (SCS)
Number of subjects: 448
Study 36117205 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Insulin Load (DIL) highest quartile
Number of subjects: 10000
Study 36117205 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Insulin Load (DIL) highest quartile, adjusted for confounders
Number of subjects: 10000
Study 36117205 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Insulin Load (DIL) highest quartile, further adjusted for BMI
Number of subjects: 10000
Study 36117205 — intervention group
Group type: COMPARATOR
Intervention: Dietary Insulin Index (DII)
Number of subjects: 10000
Study 36117205 — intervention group
Group type: COMPARATOR
Intervention: Dietary Insulin Load (DIL)
Number of subjects: 10000
Study 32563846 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone treatment
Number of subjects: 360
Study 32563846 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual-help group participation
Number of subjects: 360
Study 32563846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime major depressive disorder
Number of subjects: 360
Study 32563846 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal of opioid abstinence at treatment entry
Number of subjects: 360
Study 33455926 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside (IIM) 20 mg/kg
Number of subjects: 780
Study 33455926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) intravenously at inclusion and topically during surgery
Number of subjects: 780
Study 33455926 — intervention group
Group type: COMPARATOR
Intervention: Placebo for iron isomaltoside (IIM)
Number of subjects: 780
Study 33455926 — intervention group
Group type: COMPARATOR
Intervention: Placebo for tranexamic acid (TXA)
Number of subjects: 780
Study 33036579 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR‐BT + hypofractionated WPRT (25 Gy in 5 fractions)
Number of subjects: 58
Study 33036579 — intervention group
Group type: COMPARATOR
Intervention: HDR‐BT + conventionally fractionated WPRT (45 Gy in 25 fractions)
Number of subjects: 58
Study 35989346 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 30 mg every 12 hours
Number of subjects: 40
Study 35989346 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 40
Study 34125135 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cessation advice, a 1-week free sample of nicotine replacement therapy (NRT), and active referral to a community-based smoking cessation service.
Number of subjects: 1053
Study 34125135 — intervention group
Group type: COMPARATOR
Intervention: Brief cessation advice with a leaflet on hazards of perinatal exposure to tobacco smoke and the toll-free quitline telephone number.
Number of subjects: 1053
Study 32242145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (8-week course)
Number of subjects: 54
Study 32242145 — intervention group
Group type: COMPARATOR
Intervention: Mental health support as usual (control)
Number of subjects: 54
Study 36279236 — intervention group
Group type: EXPERIMENTAL
Intervention: Neodolpasse (30 mg Orphenadrine and 75 mg Diclofenac)
Number of subjects: 20
Study 36279236 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with Morphine
Number of subjects: 20
Study 36279236 — intervention group
Group type: EXPERIMENTAL
Intervention: Neodolpasse
Number of subjects: 20
Study 36279236 — intervention group
Group type: COMPARATOR
Intervention: PCA with Morphine
Number of subjects: 20
Study 34959784 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Atlantic diet intervention (educational sessions, cooking classes, written material, and foods)
Number of subjects: 250
Study 34959784 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual lifestyle)
Number of subjects: 250
Study 34959784 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in bodyweight per unit increment of 'Frieds' score
Number of subjects: 250
Study 34959784 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in bodyweight per unit increment of 'Fruits, vegetables, and dairy products' score
Number of subjects: 250
Study 32727835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR) 600 mg
Number of subjects: 102
Study 32727835 — intervention group
Group type: COMPARATOR
Intervention: Control (interferon beta or no disease-modifying therapy)
Number of subjects: 102
Study 32727835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR2 group)
Number of subjects: 102
Study 34592768 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental endotracheal tube (ETT) with color scale
Number of subjects: 108
Study 34592768 — intervention group
Group type: COMPARATOR
Intervention: Numeric endotracheal tube (ETT) scale
Number of subjects: 108
Study 33881710 — intervention group
Group type: COMPARATOR
Intervention: O group (warm environment)
Number of subjects: 40
Study 33881710 — intervention group
Group type: EXPERIMENTAL
Intervention: P group (passive acclimation)
Number of subjects: 40
Study 33881710 — intervention group
Group type: EXPERIMENTAL
Intervention: A group (active acclimation)
Number of subjects: 40
Study 33881710 — intervention group
Group type: COMPARATOR
Intervention: CTRL group (comfortable conditions)
Number of subjects: 40
Study 32641340 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (enteral nutrition with reduced carbohydrates)
Number of subjects: 0
Study 32641340 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition (control)
Number of subjects: 0
Study 35669738 — intervention group
Group type: EXPERIMENTAL
Intervention: ONLINE (interactive web-based weight loss program)
Number of subjects: 92
Study 35669738 — intervention group
Group type: COMPARATOR
Intervention: CON (non-interactive web-based weight loss program)
Number of subjects: 92
Study 34652087 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (12 weeks, 3-4 sessions per week, 30-60 minutes)
Number of subjects: 29
Study 34652087 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in physical activity)
Number of subjects: 29
Study 34894702 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular infiltration (PAI) with 100 mL cocktail solution (ropivacaine 20 mL, ketorolac 2 mL, epinephrine 1 mL mixed with normal saline)
Number of subjects: 60
Study 34894702 — intervention group
Group type: COMPARATOR
Intervention: Pericapsular nerve group (PENG) block with 30 mL of 0.5% ropivacaine
Number of subjects: 60
Study 34118411 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrospun fibers of amorphous solid dispersion (ASD) of itraconazole and poly(vinylpyrrolidone‐co‐vinyl acetate)
Number of subjects: 0
Study 34118411 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous processing of milled drug‐loaded electrospun materials to tablet form
Number of subjects: 0
Study 35272318 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchor-based device
Number of subjects: 43
Study 35272318 — intervention group
Group type: COMPARATOR
Intervention: Suture-capturing device
Number of subjects: 43
Study 33896388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg + B vitamins + green tea + rhodiola
Number of subjects: 100
Study 33896388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg + B vitamins + rhodiola
Number of subjects: 100
Study 33896388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg + B vitamins + green tea
Number of subjects: 100
Study 33896388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32174625 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized oral health educational video (Group A)
Number of subjects: 68
Study 32174625 — intervention group
Group type: EXPERIMENTAL
Intervention: Sign language (Group B)
Number of subjects: 68
Study 33475748 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA epitope‐matched (HEM) platelet transfusions
Number of subjects: 0
Study 33475748 — intervention group
Group type: COMPARATOR
Intervention: HLA standard antigen‐matched (HSM) platelet transfusions
Number of subjects: 0
Study 35006001 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (AppAlone)
Number of subjects: 117
Study 35006001 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention+coaching (AppCoach)
Number of subjects: 117
Study 35006001 — intervention group
Group type: COMPARATOR
Intervention: in‐person intervention (Control)
Number of subjects: 117
Study 35341666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine hemoadsorber integrated into the cardiopulmonary bypass circuit
Number of subjects: 19
Study 35341666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cytokine hemoadsorber)
Number of subjects: 19